Prescription medicines transparency measures: Implementation of generic medicines early notification to innovators of an application and publication of innovator application

The submission to the Therapeutic Goods Administration was prepared by the Intellectual Property Committee of the Business Law Section.

The Committee makes the following comments in relation to the consultation regarding ‘Prescription medicines transparency measures: Implementation of generic medicines early notification to innovators of an application and publication of innovator application’ (March 2020).

You can read the full submission below.

Last Updated on 05/06/2020

Share

• Share this on Twitter
• Share this on LinkedIn
• Share this on Facebook

Tags

• Submissions Business Law Intellectual Property

Most recent items in Business Law Section

Trending Items in Business Law Section